Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment with the DPY30-binding peptides significantly inhibited the growth of MLL-rearranged leukemia and other MYC-dependent hematologic cancer cells.
|
31251903 |
2019 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Deregulation of cellular metabolism, leading to development of leukemia, occurs through abnormally high expression of transcription factors such as MYC and Ecotropic Virus Integration site 1 protein homolog (EVI1).
|
31649131 |
2019 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we describe a novel oral active small molecule analog of berbamine, tosyl chloride-berbamine (TCB), that efficiently eliminates MYC-positive leukemia in vitro and in vivo.
|
31247466 |
2019 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MYC is a transcription factor that is hyperactive in a large proportion of cancers including leukemia but is difficult to target in therapy.
|
31273062 |
2019 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we provide evidence showing that HHT inhibits the activity of leukemia-initiating cells (Lin<sup>-</sup>/Sca-1<sup>-</sup>/c-kit<sup>+</sup>; LICs) in a t(8;21) murine leukemia model and exerts a down-regulating effect on MYC pathway genes in human t(8;21) leukemia cells (Kasumi-1).
|
30659143 |
2019 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Proscillaridin A anticancer activity was investigated against a panel of human leukemia and solid tumor cell lines with different MYC expression levels, overexpression in vitro systems and leukemia stem cells.
|
31196146 |
2019 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
UFD1 contributes to MYC-mediated leukemia aggressiveness through suppression of the proapoptotic unfolded protein response.
|
29743725 |
2018 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
c-MYC and reactive oxygen species play roles in tetrandrine-induced leukemia differentiation.
|
29700286 |
2018 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This newly discovered JAK/STAT-MYC-biosynthesis axis may provide opportunities for the development of novel therapeutic strategies in treating this subtype of leukemia.
|
29148541 |
2018 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Yet, retroviral insertional mutagenesis screens identify <i>RUNX</i> genes as collaborating oncogenes in MYC-driven leukemia mouse models.
|
28790107 |
2017 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
|
26791235 |
2016 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The induction of BIMin the MYC- and RAS-driven leukemia is mediated by the downregulation of miR-17-92.
|
27095570 |
2016 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Vitamin K2 and cotylenin A synergistically induce monocytic differentiation and growth arrest along with the suppression of c-MYC expression and induction of cyclin G2 expression in human leukemia HL-60 cells.
|
26046133 |
2015 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Loss of CXCR4 targeted key T-ALL regulators, including the MYC pathway, and decreased leukemia initiating cell activity in vivo.
|
26058075 |
2015 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently inhibitors of bromodomain and extra-terminal (BET) family proteins have shown antitumor effects through the suppression of MYC in leukemia and lymphoma.
|
25299775 |
2014 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have shown that the c-Myc promoter quadruplex-forming sequence Pu-27 selectively kills transformed cells (Sedoris, K. C., Thomas, S. D., Clarkson, C. R., Muench, D., Islam, A., Singh, R., and Miller, D. M. (2012) Genomic c-Myc quadruplex DNA selectively kills leukemia.Mol.Cancer Ther.11, 66-76).
|
24464582 |
2014 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have previously shown that all six members of the anti-apoptotic BCL2 gene family can cooperate with (myelocytomatosis oncogene) MYC in a mouse model of leukemia, but three of them are significantly less potent contributors to leukemogenicity than the other three.
|
22233804 |
2012 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that AFF4/SEC could be a potential therapeutic target for the treatment of leukemia or other cancers associated with MYC overexpression.
|
22547686 |
2012 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia.
|
23079661 |
2012 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of BET bromodomain-promoter interactions and subsequent reduction of MYC transcript and protein levels resulted in G(1) arrest and extensive apoptosis in a variety of leukemia and lymphoma cell lines.
|
21949397 |
2011 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A pediatric B lineage leukemia with coincident MYC and MLL translocations.
|
20829716 |
2011 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that KIT mutations lead to MYC-dependent miR-29b repression and increased levels of the miR-29b target Sp1 in KIT-driven leukemia.
|
20385359 |
2010 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Concomitant and successive amplifications of MYC in APL-like leukemia.
|
20113841 |
2010 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Transformation from follicular lymphoma to high-grade B-cell lymphoma/leukemia with additional t(2;8)(p12;q24), with inverse expressions of c-MYC and BCL-2, and light-chain switch.
|
19351371 |
2009 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Dual-hit lymphoma/leukemia is a rare but distinct mature B-cell neoplasm with an extremely poor prognosis characterized by frequent extranodal involvement and central nervous system progression with either of the translocation partners of MYC.
|
19535347 |
2009 |